Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
TScan Therapeutics (TCRX)
NASDAQ:TCRX
TScan Therapeutics (TCRX) Stock Price & Analysis
149 Followers
TCRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.93 - $9.36
Previous Close$8.9
Volume177.73K
Average Volume (3M)209.23K
Market Cap
$470.48M
Enterprise Value$370.87M
Total Cash (Recent Filing)$192.04M
Total Debt (Recent Filing)$92.43M
Price to Earnings (P/E)-7.0
Beta0.42
Next Earnings
Aug 08, 2024EPS Estimate
-$0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.28
Shares Outstanding52,862,805
10 Day Avg. Volume165,746
30 Day Avg. Volume209,232
Standard Deviation0.28
R-Squared0.03
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)3.15
Price to Sales (P/S)20.54
Price to Cash Flow (P/CF)-5.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue17.62
Enterprise Value/Gross Profit17.62
Enterprise Value/Ebitda-9.58
Forecast
1Y Price Target
$12.33Price Target Upside37.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
TScan Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsTScan's TCR-T’s continue to show promising results in attacking both solid and liquid tumors, demonstrating the potential to differentiate in the treatment of various cancers.
Financial StabilityTScan has a solid cash runway into 4Q26, providing financial stability and the ability to fund ongoing research and trials.
Product DevelopmentTScan Therapeutics is developing treatments with early promising data on reduced relapse rates for AML, ALL and MDS with TSC 100/101 post transplant.
Bears Say
Clinical Trial ResultsIn the control group, two out of six patients experienced relapse and another passed away, indicating a significant difference in outcomes compared to the treatment groups.
Financial HealthReturn on Equity TTM is -65.28%, highlighting current operational losses which could be a concern for potential investors.
Financial SustainabilityA high annualized cash burn rate indicates significant ongoing expenses relative to the company's financial resources.
---
Ownership Overview
21.58% Insiders
5.78% Mutual Funds
62.73% Other Institutional Investors
9.92% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
TCRX FAQ
What was TScan Therapeutics’s price range in the past 12 months?
TScan Therapeutics lowest stock price was $1.93 and its highest was $9.36 in the past 12 months.
What is TScan Therapeutics’s market cap?
Currently, no data Available
When is TScan Therapeutics’s upcoming earnings report date?
TScan Therapeutics’s upcoming earnings report date is Aug 08, 2024 which is in 82 days.
How were TScan Therapeutics’s earnings last quarter?
TScan Therapeutics released its earnings results on May 13, 2024. The company reported -$0.32 earnings per share for the quarter, missing the consensus estimate of -$0.259 by -$0.061.
Is TScan Therapeutics overvalued?
According to Wall Street analysts TScan Therapeutics’s price is currently Undervalued.
Does TScan Therapeutics pay dividends?
TScan Therapeutics does not currently pay dividends.
What is TScan Therapeutics’s EPS estimate?
TScan Therapeutics’s EPS estimate is -$0.28.
How many shares outstanding does TScan Therapeutics have?
TScan Therapeutics has 48,586,216 shares outstanding.
What happened to TScan Therapeutics’s price movement after its last earnings report?
TScan Therapeutics reported an EPS of -$0.32 in its last earnings report, missing expectations of -$0.259. Following the earnings report the stock price went up 3.622%.
Which hedge fund is a major shareholder of TScan Therapeutics?
Among the largest hedge funds holding TScan Therapeutics’s share is Baker Bros Advisors LP. It holds TScan Therapeutics’s shares valued at 16M.
---
TScan Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.33 (37.31% Upside)
$12.33 (37.31% Upside)
Blogger Sentiment
Bullish
TCRX Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.5%
Last 30 Days ▼ 7.8%
Last 30 Days ▼ 7.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
123.05%
12-Months-Change
Fundamentals
Return on Equity
-96.32%
Trailing 12-Months
Asset Growth
38.75%
Trailing 12-Months
Company Description
TScan Therapeutics
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
---
TCRX Stock 12 Month Forecast
Average Price Target
$12.33
▲(37.31% Upside)
Technical Analysis
Applied Therapeutics
―
Adverum Biotechnologies
―
Arvinas Holding Company
―
Kala Pharmaceuticals
―
Best Analysts Covering TCRX
1 Year
1 Year Success Rate
5/6 ratings generated profit
1 Year Average Return
+37.85%
assigned a buy rating 3 days ago
Copying Sam Slutsky's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +37.85% per trade.
---